ALK is an inclusion eligibility criterion in 2 clinical trials for primary mediastinal B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and primary mediastinal B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open) [3].

BCL2 is an inclusion eligibility criterion in 13 clinical trials for primary mediastinal B-cell lymphoma, of which 13 are open and 0 are closed. Of the trials that contain BCL2 status and primary mediastinal B-cell lymphoma as inclusion criteria, 6 are phase 1 (6 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 2 are phase 3 (2 open) [3].

BCL6 is altered in 11.11% of primary mediastinal B-cell lymphoma patients [2].

BCL6 is an inclusion eligibility criterion in 12 clinical trials for primary mediastinal B-cell lymphoma, of which 12 are open and 0 are closed. Of the trials that contain BCL6 status and primary mediastinal B-cell lymphoma as inclusion criteria, 6 are phase 1 (6 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [3].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for primary mediastinal B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

IGH is an inclusion eligibility criterion in 1 clinical trial for primary mediastinal B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

IRF4 is altered in 23.08% of primary mediastinal B-cell lymphoma patients [2].

IRF4 is an inclusion eligibility criterion in 1 clinical trial for primary mediastinal B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is altered in 11.11% of primary mediastinal B-cell lymphoma patients [2].

MYC is an inclusion eligibility criterion in 13 clinical trials for primary mediastinal B-cell lymphoma, of which 13 are open and 0 are closed. Of the trials that contain MYC status and primary mediastinal B-cell lymphoma as inclusion criteria, 6 are phase 1 (6 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 2 are phase 3 (2 open) [3].